The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Novo Nordisk markets its blockbuster semaglutide (GLP-1) medicines as Ozempic pre-filled pens and Rybelsus oral ... The study found that the drug was not associated with a risk of adverse ...

As Ozempic and other GLP-1 drugs explode in popularity ... reported seizing 369 potentially fake Ozempic pens between January and October in 2023, marking the first identification of such ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

off dopaminergic medication at 96 weeks, increased (worsened) by a mean of 5.7 and 4.5 points in the exenatide and placebo groups, respectively (adjusted coefficient for the effect of exenatide, 0.92; ...